Skip to main content
Article
What Have We Learned about the Treatment of Type 2 Diabetes? The Evolving Paradigms
American Journal of Therapeutics
  • Jeffrey S. Freeman, Philadelphia College of Osteopathic Medicine
  • Edward S. Horton
Document Type
Article
Publication Date
11-1-2012
Abstract
Insulin, the first treatment for diabetes, was discovered >90 years ago. Since then, many new types of insulin have become available, including analogs that more closely mimic the characteristics of endogenous insulin. In addition, oral antidiabetes drugs and other types of injectable therapies have been approved for the treatment of patients with type 2 diabetes. As newer treatments are approved for type 2 diabetes, the choice and-paradoxically-the complexity of treatment increases. The potential benefits of all treatment options must be carefully balanced against potential adverse events to truly analyze the overall efficacy, safety, tolerability, and potential long-term effects. The manner in which outcomes are assessed and the methods employed to make such assessments have changed over time. This review will address these issues as they are related to therapies for type 2 diabetes, including insulin, oral antidiabetes drugs, and incretin-based agents.
PubMed ID
23154228
Comments

This article was published in American Journal of Therapeutics, Volume 19, Issue 6, November 2012, Pages 449-64.

The published version is available at http://dx.doi.org/10.1097/MJT.0b013e31826fc5e5

Copyright: © 2012 Lippincott Williams & Wilkins, Inc.

Citation Information
Jeffrey S. Freeman and Edward S. Horton. "What Have We Learned about the Treatment of Type 2 Diabetes? The Evolving Paradigms" American Journal of Therapeutics Vol. 19 Iss. 6 (2012) p. 449 - 464
Available at: http://works.bepress.com/jeffrey_freeman/1/